14. Referenties

1.    Berden, F.A., et al., Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era. Neth J Med, 2014. 72(8): p. 388-400.
2.    European Association for the Study of the Liver. Electronic address, e.e.e., EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol, 2017. 66(1): p. 153-194.
3.    Recommendations for Testing, Managing, and Treating Hepatitis C. September 2017.
4.    European Association for the Study of the Liver. Electronic address, e.e.e., EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol, 2015.
5.    van der Meer, A.J., et al., Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA, 2012. 308(24): p. 2584-93.
6.    Recommendations for Testing, Managing, and Treating Hepatitis C. www.hcvguidelines.org, 2016.
7.    Tacke., F., et al., TREATMENT OF HCV GENOTYPE 2 WITH SOFOSBUVIR AND RIBAVIRIN RESULTS IN LOWSVR RATES IN A REALWORLD COHORT (GERMAN HEPATITIS C-REGISTRY, DHC-R). EASL abstract, 2016.
8.    Susser., S., et al., PREVALENCE AND CLINICAL IMPORTANCE OF HEPATITIS C VIRUS GENOTYPE 2 K/1B CHIMERAS. EASL abstract, 2016.
9.    Arends, J.E., et al., Treatment of acute hepatitis C virus infection in HIV+ patients: Dutch recommendations for management. Neth J Med, 2011. 69(1): p. 43-9.
10.    Lamers, M.H., et al., Treatment of hepatitis C monoinfection in adults--Dutch national guidelines. Neth J Med, 2013. 71(7): p. 377-85.
11.    Boesecke, C. Acute HCV spontaneaous clearance rates low among HIV coinfected. in CROI 2018. Boston.
12.    Basu, P.P., et al., Sofosbuvir and Ledipasvir versus Sofosbuvir and Simprevir combination therapy in the management of acute hepatitis C: a randomized open label prosptective clinical pilot study. SLAM C study. Journal of Hepatology, 2016. 64: p. S631–S832.
13.    Deterding, K., et al., Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. The Lancet Infectious Diseases, 2017. 17(2): p. 215-222.
14.    Rockstroh, J.K., et al., Ledipasvir–sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. The Lancet Gastroenterology & Hepatology, 2017. 2(5): p. 347-353.
15.    EMA. Summary of prodcut characteristics: Pegasys. 2007  [cited 2015 June 5]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000395/WC500039195.pdf.
16.    Barril, G., et al., Pegylated interferon-α2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers. Alimentary Pharmacology & Therapeutics, 2004. 20(1): p. 37-44.
17.    EMA, Summary of Product Characteristics: PegIntron. 2010.
18.    Gupta, S.K., et al., Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. British Journal of Clinical Pharmacology, 2007. 64(6): p. 726-732.
19.    EMA, Copegus: prescibing information. 2011.
20.    Bruchfeld, A., et al., Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat, 2006. 13(5): p. 316-21.
21.    Fda. Copegus : Prescribing information. 2011; Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
22.    EMA. Olysio: Product Information. 2014  [cited 2015 February 15]; Available from: http://ec.europa.eu/health/documents/community-register/2014/20140514128513/anx_128513_en.pdf.
23.    Nazario., H.E., M. Ndungu., and A.A. Modi, Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min. EASL abstract, 2016.
24.    Comellas, B., Treatmet of HCV withs imeprevir associated to daclatasvir in patients with stage 4 and 5 chornic renal failure. EASL abstract, 2016.
25.    Nazario, H.E., sofosbuvir-based, ribavirin-free regimens in patients with chronic hepatitis C and end-stage renal disease: a look at safety, tolerability and efficacy. EASL abstract, 2016.
26.    EMA. Summary of Product Characteristics: Sovaldi. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdf
27.    Saxena, V., et al., Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real-world experience from HCV-TARGET, in Annual Meeting of the European Association for the Study of the Liver (EASL). 2015: Vienna.
28.    Gane, E.J., et al., Safety, Antiviral Efficacy, and Pharmacokinetics of Sofosbuvir in Patients With Severe Renal Impairment in Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2014: Boston.
29.    Nazario, H.E., M. Ndungu, and A. Modi, Safety and efficacy of sofosbuvir + simeprevir without ribavirin in hepatitis C genotype 1-infected patients with end-stage renal disease or GFR<30ml/min, in Annual Meeting of the European Association for the Study of the Liver (EASL). 2015: Vienna.
30.    Beinhardt, S., et al., Real life experience with interferon/ribavirin free antiviral treatment in renal transplant recipients and end stage renal disease patients on dialysis infected with hepatitis C virus, in Annual Meeting of the European Association for the Study of the Liver (EASL). 2015: Vienna.
31.    Desnoyer, A., et al., Sofosbuvir in haemodialysis: 400mg daily only the day of haemodialysis? , in 16th Workshop of Clinical pharmacology of HIV and Hepatitis Therapy. 2015: Washington, DC.
32.    Desnoyer, A., et al., Sofosbuvir-containing regimen for HCV infection in hemodialysis patients: 400 mg daily or only on the day of hemodialysis. EASL abstract, 2016.
33.    EMA. Daklinza: Summary of Product Characteristics. 2014; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf.
34.    EMA. Summary of Product Characteristics: Viekirax. 2015  [cited 2015 June 5]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003839/WC500183997.pdf.
35.    Pockros, P.J., et al., Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 study, in Annual Meeting of the European Association for the Study of the Liver (EASL). 2015: Vienna.
36.    EMA. Summary of Product Characteristics: Exviera. 2015  [cited 2015 June 5]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003837/WC500182233.pdf.
37.    EMA. Harvoni: Product Information. 2014 November 17 [cited 2015 February 15]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003850/WC500177995.pdf.
38.    EMA. Summary of Product Characteristics: Epclusa. 2016 [cited 2017 May 17]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004210/WC500211151.pdf.
39.    EMA. Summary of Product Characteristics: Zepatier. 2016 [cited 2017 May 17]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004126/WC500211238.pdf
40.    EMA. Summary of Product Characteristics: Maviret. 2017. [cited 2018 March 2]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004430/WC500233677.pdf.
41.    EMA. Summary of Product Characteristics: Vosevi. 2017. [cited 2018 March 2]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004350/WC500235373.pdf
42.    Nazario, H.E., M. Ndungu, and A.A. Modi, Sofosbuvir and Simeprevir in Hepatitis C genotype 1- patients with End-Stage Renal Disease on hemodialysis or GFR <30mL/min. Liver Int, 2015.
43.    Hundemer, G.L., et al., Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond), 2015. 47(12): p. 924-9.
44.    Maan, R., et al., Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol, 2016. 14(12): p. 1821-1830 e6.
45.    Back, D.J. and D.M. Burger, Interaction Between Amiodarone and Sofosbuvir-based Treatment for Hepatitis C Virus Infection: Potential Mechanisms and Lessons to be Learned. Gastroenterology, 2015. 149(6): p. 1315-7.
46.    Fontaine, H., et al., Bradyarrhythmias Associated with Sofosbuvir Treatment. N Engl J Med, 2015. 373(19): p. 1886-8.




index.html